stride semaglutide boosts walking ability in diabetes patients with peripheral artery disease, clinical trial finds STRIDE trial analysis confirms potential

GLP-1 weight-loss drugs are cutting calories and grocery bills, according to a new study from Cornells SC Johnson College of Business using data from Numerator

Nunns M et al

The program also includes regular medical check-ins with your healthcare provider to monitor your progress and make any necessary adjustments to your treatment plan

If terzapatide was a dual agonist, GLP-GIP, Retatrutide is the triple agonist that adds to it a glucagon component, which is absolutely just shredding, shredding liver fat

'Lipo-literacy' fuelling weight loss as a moral panic Fuelling a surge in diet culture, according to RMIT University's Dr Natalie Jovanovski, is the collision of "health and aesthetic concerns"